Form 4 for IDXX Idexx Laboratories
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-11 · accession 0000874716-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-12 | 2025-02-11 | IDXX | Erickson Michael G | EVP | M - OptEx | $67.85 | +1,544 | 20.8K | +8% | +$104.8K |
| D | 2025-02-12 | 2025-02-11 | IDXX | Erickson Michael G | EVP | M - OptEx | — | -1,544 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-11 | M | A | 1,544 | $67.85 | 20,836.36 | D | — | — | |
| 2 | Derivative | Incentive Stock Option (right-to-buy) | 2025-02-11 | M | D | 1,544 | — | 0 | D | $67.85 · — to 2026-02-13 | 1,544 Common Stock | (F2) Not applicable. (F1) Grant of option to buy 1,544 shares of Issuer common stock that vested on February 14, 2021. |